Brian Stephenson Acquires 9,230 Shares of Sensei Biotherapeutics (NASDAQ:FTH) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson bought 9,230 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was bought at an average price of $24.36 per share, with a total value of $224,842.80. Following the completion of the acquisition, the chief financial officer owned 17,413 shares of the company’s stock, valued at $424,180.68. This trade represents a 112.79% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Sensei Biotherapeutics Stock Performance

Shares of FTH opened at $24.67 on Friday. Sensei Biotherapeutics, Inc. has a 1 year low of $6.32 and a 1 year high of $36.76.

Analyst Upgrades and Downgrades

FTH has been the subject of several recent analyst reports. Weiss Ratings initiated coverage on Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating for the company. BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. Finally, HC Wainwright initiated coverage on Sensei Biotherapeutics in a research report on Monday. They set a “buy” rating and a $60.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Sensei Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.